Peeling Back The Layers: Exploring Nurix Therapeutics Through Analyst Insights

In the preceding three months, 11 analysts have released ratings for Nurix Therapeutics (NASDAQ:NRIX), presenting a wide array of perspectives from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 7 4 0 0 0
Last 30D 0 1 0 0 0
1M Ago 2 1 0 0 0
2M Ago 3 2 0 0 0
3M Ago 2 0 0 0 0

In the assessment of 12-month price targets, analysts unveil insights for Nurix Therapeutics, presenting an average target of $28.73, a high estimate of $35.00, and a low estimate of $20.00. This upward trend is evident, with the current average reflecting a 0.45% increase from the previous average price target of $28.60.

Breaking Down Analyst Ratings: A Detailed Examination

A clear picture of Nurix Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Joseph Catanzaro Piper Sandler Maintains Overweight $35.00 $35.00
Stephen Willey Stifel Maintains Buy $27.00 -
Gil Blum Needham Maintains Buy $31.00 $31.00
Sudan Loganathan Stephens & Co. Announces Overweight $20.00 -
Gregory Renza RBC Capital Raises Outperform $23.00 $22.00
Joel Beatty Baird Raises Outperform $25.00 $24.00
Gil Blum Needham Maintains Buy $31.00 -
Gil Blum Needham Maintains Buy $31.00 -
Gil Blum Needham Maintains Buy $31.00 -
Gil Blum Needham Maintains Buy $31.00 $31.00
Gil Blum Needham Maintains Buy $31.00 -

Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nurix Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company. Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nurix Therapeutics compared to the broader market. Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Nurix Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Nurix Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Nurix Therapeutics analyst ratings.

If you are interested in following small-capstock newsand performance you can start by tracking it here.

Discovering Nurix Therapeutics: A Closer Look

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Key Indicators: Nurix Therapeutics's Financial Health

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Nurix Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 29 February, 2024, the company achieved a revenue growth rate of approximately 30.75%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Nurix Therapeutics's net margin excels beyond industry benchmarks, reaching -250.33%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Nurix Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -22.49%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Nurix Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -12.43%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.

The Basics of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Latest Ratings for NRIX

DateFirmActionFromTo
Feb 2022Wells FargoInitiates Coverage OnEqual-Weight
Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy
Oct 2021SVB LeerinkMaintainsOutperform

View More Analyst Ratings for NRIX

View the Latest Analyst Ratings

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.